Get the Stockscreener App
14.85
5.73%
0.805
Pre-market:
15.11
0.26
+1.75%
Atara Biotherapeutics Inc stock is traded at $14.85, with a volume of 51,373.
It is up +5.73% in the last 24 hours and up +3.63% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$14.04
Open:
$13.99
24h Volume:
51,373
Relative Volume:
0.99
Market Cap:
$104.29M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.5765
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
+2.48%
1M Performance:
+3.63%
6M Performance:
+85.86%
1Y Performance:
+66.67%
1-Day Range:
$13.99
$14.89
1-Week Range:
$13.30
$15.74
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
14.85 | 98.64M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Is Atara Biotherapeutics Inc. (AT20) stock nearing a technical breakoutQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock beat value stocks2025 Buyback Activity & Fast Gain Stock Trading Tips - newser.com
Live market analysis of Atara Biotherapeutics Inc.Weekly Trade Summary & Detailed Earnings Play Strategies - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock sustain uptrend momentumMarket Volume Report & Capital Efficient Trade Techniques - newser.com
Will Atara Biotherapeutics Inc. stock maintain growth storyQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Custom strategy builders for tracking Atara Biotherapeutics Inc.Trade Analysis Report & Fast Gain Stock Trading Tips - newser.com
How hedge fund analytics apply to Atara Biotherapeutics Inc. stockNew Guidance & Verified Momentum Stock Watchlist - newser.com
Is Atara Biotherapeutics Inc. stock supported by strong fundamentals2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
How Atara Biotherapeutics Inc. (AT20) stock performs during market turbulenceJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
How to recover losses in Atara Biotherapeutics Inc. stockLayoff News & Safe Entry Zone Tips - newser.com
Will Atara Biotherapeutics Inc. stock attract ESG investorsJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Is Atara Biotherapeutics Inc. forming a bottoming baseMarket Trend Review & Reliable Volume Spike Alerts - newser.com
Institutional scanner results for Atara Biotherapeutics Inc.July 2025 WrapUp & Real-Time Market Sentiment Reports - newser.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Will a bounce in Atara Biotherapeutics Inc. offer an exit2025 Trading Recap & Intraday High Probability Alerts - newser.com
Immatics (NASDAQ: IMTX) names Amie Krause CPO to lead HR amid commercial-stage transition - Stock Titan
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):